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Abstract: The World Health Organization has reported that counterfeit medicines potentially 
make up more than 50% of the global drug market, with a significant proportion of these fake 
products being encountered in developing countries. This occurrence is attributed to a lack of 
effective regulation and a weak enforcement capacity existing in these countries, with an increase 
in this trade resulting from the growing size and sophistication of drug counterfeiters. In addition, 
due to both cost and lack of availability of medicines, consumers in developing countries are more 
likely to seek out these inexpensive options. The World Health Organization is mindful of the 
impact of counterfeit drugs on consumer confidence in health care systems, health professionals, 
the supply chain, and genuine suppliers of medicines and medical devices. Antibiotics, antituber-
culosis drugs, and antimalarial and antiretroviral drugs are frequently targeted, with reports of 
60% of the anti-infective drugs in Asia and Africa containing active pharmaceutical ingredients 
outside their pharmacopoeial limits. This has obvious public health implications of increasing 
drug resistance and negating all the efforts that have already gone into the provision of medicines 
to treat these life threatening conditions in the developing world. This review, while focusing on 
counterfeit medicines and medical devices in developing countries, will present information on 
their impact and how these issues can be addressed by regulation and control of the supply chain 
using technology appropriate to the developing world. The complexity of the problem will also 
be highlighted in terms of the definition of counterfeit and substandard medicines, including gray 
pharmaceuticals. Although this issue presents as a global public health problem, outcomes in 
developing countries where counterfeit drugs to treat malaria, tuberculosis, and human immuno-
deficiency virus/acquired immunodeficiency syndrome not only result in drug resistance, but a 
number of deaths from the untreated disease, is in stark contrast with the developed world, where 
lifestyle drugs such as sildenafil (Viagra®) are most commonly counterfeited.
Keywords: counterfeit, medicines, devices, developing countries, drug resistance, public 
health
Introduction
Product counterfeiting is increasing worldwide, both in terms of the volume, level 
of sophistication, and in the number the countries affected, both in the developed 
and developing world. Despite the diversity of products counterfeited, counterfeit-
ers are often referred to as a homogeneous group. Staake et al1 have however clas-
sified counterfeiters into five groups: 1) disaggregators; 2) imitators; 3) fraudsters; 
4) desperados; and 5) smugglers, to better address the issue of counterfeiting in the 
market. These groups were classified according to the visual and functional quality of 
the counterfeit products, in addition to product complexity. The disaggregator group 
encompasses counterfeit products with an average visual quality, medium functional 
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quality, and low to medium product complexity, while the 
imitators represent those products with the highest visual and 
functional quality and product complexity. The term imitator 
is appropriately used in this case, as these counterfeits closely 
resemble the genuine products. Although the smuggler group, 
which includes products with average to high visual and func-
tional quality and medium complexity, resembles the imitator 
group, the major difference is the circumvention of taxes by 
this group. The fraudster group includes those products of 
high visual but low functional quality, which because of their 
medium complexity are likely to pass as genuine. Because 
of the deception involved, and the potential financial loss to 
the buyer, the term fraudster was deemed appropriate. For 
pharmaceutical products, which represent 9% of the sample 
in this study, all counterfeiters were classified as desperados. 
This group represents products where the visual quality is 
medium to high, while the functional quality and product 
complexity is low. They are said to pose a severe threat 
to consumers and as such, this places the counterfeiters into 
conflict with enforcement agencies such as regulators, with 
the term desperados relating to the unscrupulous nature of 
this group. Counterfeiters have unfortunately also evolved 
over time with the transformation of a counterfeit producer 
to an illicit manufacturer occurring, which is particularly 
relevant to counterfeited pharmaceutical products.
The term counterfeit drug has been defined differently in 
different countries limiting both the exchange of information 
between countries and a real understanding of the extent of 
the problem globally. To address this problem, the World 
Health Organization (WHO) has proposed that a counter-
feit medicine (branded or generic products) be defined as 
one which is deliberately and fraudulently mislabeled with 
respect to identity and/or source.2 This however should not 
be confused with the term substandard medicines, which may 
be described as genuine drug products which do not meet the 
required quality specifications. “Gray pharmaceuticals” is a 
term recently used for the marketing of competitive brands 
by illicit profiteers who do not have regulatory approval.
Counterfeit products are those: 1) without active pharma-
ceutical ingredients (APIs), including the wrong ingredients, 
which may or may not be toxic. In this case, the API is often 
replaced by inexpensive substitutes such as flour, curcuma, 
or cassava in oral formulations and water in injections. Even 
more of a problem is that these products may contain toxic or 
pathogenic chemical impurities, which have potentially lethal 
consequences, with an example being methanol detected in a 
counterfeited amoxicillin injection;2 2) with incorrect quanti-
ties of these APIs, where these products usually contain less 
than the stated amount. Examples here are less expensive or 
outdated drugs, which may be repackaged, such as diazepam 
syrup which was sold as cotrimoxazole syrup in Nigeria and 
erythromycin sold as the antimalarial, artesunate, in south-
east Asia. Another example is praziquantel, used against 
schistosomiasis, where the forgery was detected because 
each tablet should have contained 600 mg of API and the 
tablets only weighed 480 mg in total. In addition, the leaf-
let was written in poor English, without any manufacturer 
identification;3 3) with fake or counterfeit packaging, where 
the packaging may be copied, or in some cases modified, to 
escape prosecution for infringing intellectual property.2
The United States Food and Drug Administration have 
reported on the existence of counterfeit and substandard med-
icines in both developed and developing countries, with 25% 
(range between 10%–30%) of the counterfeit and substandard 
medicines being consumed in developing countries, includ-
ing Latin America, southeast Asia, or sub-Saharan Africa.4 
Evidence from 17 countries5 has revealed that there is a 
relationship between price and the poor quality of medicines. 
The purchasers of these products are also likely to suspect 
that they are of low quality, if in addition to low price, the 
product is generic and available from a pharmacy or outlet, 
with a poor appearance. It must however be stated that even 
if all these factors are present, it cannot be assumed that the 
products are counterfeit. These findings do present informa-
tion on the economics of poor quality drugs and the extent 
to which consumers can draw accurate conclusions relating 
quality to both price and the appearance of the pharmacy. 
Unfortunately the poor consumer in the developing world, 
who will inevitably have a low income and limited literacy, 
will still choose to purchase on the assumption that it is bet-
ter than no treatment at all. These findings concur with those 
of Furnham and Valgeirsson6 who reported on the effect of 
life values and materialism on buying counterfeit products. 
Their study was conducted on a sample of educated British 
people who were willing to buy counterfeit pens and clothing 
for a good price. They were however not prepared to do so in 
the case of medicines. Stumpf and Chaudhry7 also explored 
the effect of country on the counterfeit trade. In 2006, most 
(54%) of the counterfeit drugs detected were manufactured 
in India, with China manufacturing 21% and Hong Kong 
manufacturing 10%. The site of manufacture for these drugs 
is reported to take place more readily in countries which 
themselves neither have good purchasing practices nor good 
regulation. However, the fact that there are few published data 
limits the accurate estimation of the extent of the problem 
and its impact on public health. Although the incidence of 
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counterfeit medicines is low in the developed world, there 
has been an increase by 400% in the number of these drugs 
identified from 2005 to 2010 in Europe.8 The fact that this 
trade is said to be 25 times more lucrative than that of heroin 
places a perspective on and highlights the magnitude of this 
problem.8
Counterfeit medicines, unfortunately, are not a new con-
cept, with trading in these counterfeit medicines, sometimes 
referred to as fake medicines, beginning several millennia 
ago.8 In fact, it is ironic today that antibiotics are the most 
counterfeited medicines, occupying a 28% share of this 
market, when fake cinchona bark was reported as a crisis 
as early as the 1600s and fake quinine in the 1800s.9 These 
counterfeit antibiotics include mainly the “old” antibiotics 
such as beta-lactams and quinolones, which have been com-
monly used for years. Amoxicillin is reported to be the most 
counterfeited API in the world, and the cause of treatment 
failure in Papua New Guinea.10 Counterfeit anti-infective 
drugs were first reported over 25 years ago.11 Until recently, 
the published research in this area has been limited, with 
much of the information, especially in developing countries, 
found in the gray literature. In fact, most of the current litera-
ture is related to analytical approaches to detect counterfeit 
medicines, which due to cost and expertise required, have 
limited application in developing countries.
Dosage forms for oral administration, eg, tablets, syrup, 
and capsules are those most commonly counterfeited (77%), 
as opposed to injectable formulations (17%).10 This obviously 
relates to the level of sophistication of the equipment required 
to produce injectable formulations.10
A comprehensive review on understanding and fighting 
the counterfeit medicine market by Dégardin et al12 high-
lights the situation worldwide and proposes solutions to 
limit this phenomenon. Almuzaini et al13 have however also 
presented a systematic review of the literature to explore 
the evidence available, not only for counterfeit medicines 
but also for all poor quality medicines, whether counterfeit 
or substandard.
Counterfeiting of drugs – why?
WHO estimated as far back as 1991 that half of the world’s 
population at that stage did not have regular access to essen-
tial drugs, with this number reducing to 33% in sub-Saharan 
Africa.14 Although counterfeit drugs are an important issue 
in Africa, there are also a number of other constraints to 
the regular supply of essential drugs, including geographic 
 location, logistics, ensuring the integrity of the supply chain, 
and financing the supply of essential drugs. It must also 
be noted that some of these constraints also play a role in 
compounding or impacting the issue of counterfeit drugs in 
Africa.14 There are a number of factors which make medicines 
a viable and attractive option for counterfeiters, particularly in 
the developing world. These factors and their importance in 
developing countries as well as the risk rated as mild, moder-
ate, or high, are listed in Table 1. Drug products lacking in 
quality, safety, and efficacy, and that are not under regulatory 
control, may result in prolonged therapy, promote resistance, 
and cause adverse effects, which are then not reported on 
or monitored. This has potential to significantly impact on 
global public health.
Impact of counterfeit medicines  
and devices
Developing countries
The International Medical Products Anti-Counterfeiting 
Taskforce (IMPACT) was established in February 2006, to 
coordinate efforts to address the issue of counterfeit drugs,15 
as this subject has taken on a new dimension within the 
international health community. Mitigating a macroeconomic 
pandemic has attracted the attention of prominent members 
of the public health community who have commented on the 
potential outcomes of treating, eg, human immunodeficiency 
virus/acquired immunodeficiency syndrome (HIV/AIDS) 
patients with counterfeit drugs.16 IMPACT, led by WHO, 
had plans to focus on the following key areas: legislative 
and regulatory infrastructure, regulatory implementation, 
Table 1 Factors affecting the counterfeiting of drugs
Factor Explanation Importance  
in developing  
country
Risk
Government  
will and  
commitment
Drugs should not be treated  
as other commodities due  
to effect on public health
*
Drug  
regulatory  
body
Legislation does not exist 
wHO member states: 
a) 20% – well developed 
b) 50% – varied development 
c)  30% – no or nonfunctional 
regulation
**
Demand  
exceeds  
supply
Health care system lack of 
supply of medicines due to: 
a) Poverty 
b) illiteracy 
c) Rural locations
Creates a market  
for criminally  
minded people
***
High prices Price differentials Supply chain,  
poverty
**
Notes: *Denotes risk rated as mild; **denotes risk rated as moderate; ***denotes 
risk rated as high. Data from wHO.2
Abbreviation: wHO, world Health Organization.
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enforcement, technology, and communication. Table 2 pres-
ents a summary of the impact of counterfeit medicines for 
people in developing countries.
Antibiotic drugs
Acquired bacterial resistance is common in developing 
countries, with this resistance increasing to first line broad 
spectrum agents. This is of particular concern as these agents 
are inexpensive and given the budgetary constraints within 
developing countries, are often the only affordable drugs. It 
is also worrying how rapidly resistance has emerged to the 
newer agents, such as the fluoroquinolones. This has been 
attributed to the misuse of antibiotics by physicians, unskilled 
practitioners, and the public.18 In developing  countries, 
counterfeit medicines are only one aspect of poor quality 
antibiotics, with other issues including a lack of adherence 
and monitoring, degraded antibiotics often due to inadequate 
storage in both pharmacies and in the supply chain, expired 
antibiotics distributed from developed countries, and bio-
inequivalent antibiotics. Between 1981 and 1995, resistance 
to ampicillin, tetracycline, sulfonamides, chloramphenicol, 
fluoroquinolones, isoniazid, streptomycin, and rifampicin was 
shown to be increasingly prevalent across the following devel-
oping and tropical countries: Bangladesh, Brazil, Rwanda, 
Thailand, India, Kenya, and Morocco.18 As an indication of 
the problem of counterfeiting in relation to antibiotics, it 
has been reported that counterfeit drugs account for 5% of 
antibiotics sold worldwide, with this percentage a lot higher 
in developing countries.9 Counterfeiting of antibiotics in 
developed countries is a rarity, eg, in the French health care 
network there has been no reported counterfeiting of antibiot-
ics. This has been attributed to effective control of marketing, 
the supply chain, and strict enforcement by customs.9 These 
counterfeit drugs in developing countries only compete favor-
ably in these markets because of the lack of availability of 
analytical laboratories and because a substantial proportion 
of the drugs in these countries are generic, often resulting in 
the counterfeit drugs going undetected.
Because countries of sub-Saharan Africa are highly 
affected by infectious disease, and because of economics, 
corruption, and lack of regulation and control they are an 
obvious target for counterfeiters. The unfavorable outcome 
of this is that they account for 50% of the deaths due to 
infectious diseases, even though these countries only have 
12% of the world population.18 There is also a discrepancy 
in the availability of health care between rural and urban or 
metropolitan regions. Although this has been described for 
India and China, this is true for most countries, often even 
those in the developed world. Metropolitan areas are less con-
cerned with counterfeit drugs, and there are in fact  similarities 
between these urban zones in developing countries and those 
countries in the developed world.18
Antibiotics are reported to be counterfeited according to 
chemical class such as beta-lactams and the type of formula-
tion (77% for oral intake) and are often presented in a coun-
terfeited package. Antibiotic counterfeiting has implications 
for the individual and the collective population, with obvious 
industrial and economic consequences. In studies conducted 
in Burma, Cameroon, Vietnam, Cote d’Ivoire, and Nigeria, 
between 8% and 35% of the anti-infectives were found to 
be counterfeit, in most cases with the API content being out 
of the pharmacopoeial limits, with no API present, and in 
the case of the antimalarials, chloroquine being substituted 
for quinine.18
Table 2 impact of counterfeit medicines for developing countries
1.  increased mortality and morbidity: due to ingredients substituted for 
the APi, which are lethal. in the past it has been assumed that these 
ingredients were inert, eg, starch or lactose. Paracetamol adulterated 
with diethylene glycol, a renal toxin and a cheaper substitute for 
propylene glycerol or glycerol, caused the death of a number of children 
in various developing countries, including Bangladesh.17
2.  Drug resistance: due to subtherapeutic amounts of APi in the drug 
product. in developing countries this is particularly relevant to the 
supply of antibiotics, and antimalarial and antiretroviral drugs, resulting 
in the emergence of drug resistant pathogens. Combination therapy 
for TB, Hiv/AiDS, and malaria limited by poor quality artemisinin 
derivatives and similarly, poor quality TB drugs does not only result in 
treatment failure, but increases the incidence of drug resistance.
3. Reducedconfidenceinthehealthsystem:duetotheconsequencesof
these counterfeit medicines, often among patients who were skeptical 
of these essentially “western” systems at the outset. This also results 
in an increased workload for health professionals and health outlets 
suchasclinicsandpharmaciestoattempttorestorethisconfidence.
4.  economic consequences: for patients and their families, the country, 
and the providers of genuine medicines, due to a workforce which is 
often too ill to work or care for their families.
5.  Adverse effects: due to incorrect ingredients, where the effects 
may vary from being unexpected (eg, when cotrimoxazole contains 
diazepam) to causing allergic reactions (eg, artesunate tablets 
containing chloramphenicol). in addition, it cannot be assumed that 
counterfeit products containing APis will be subtherapeutic, as in 
some cases, they contain more than the stated amount and for those 
drugs with narrow therapeutic indices, this increases the potential for 
adverse effects.
6. Wastage:financiallyduetotheeffortsofgovernmentsbothinthe
developing countries, who have attempted to make these medicines 
available to patients, and to those in the developed world, who often 
sponsor the provision of these drugs to control and/or eradicate 
diseases such as TB, malaria, and Hiv/AiDS.
Note: Data from Newton et al8 and wertheimer and Norris.16
Abbreviations: APis, active pharmaceutical ingredients; Hiv/AiDS, human immuno­
deficiencyvirus/acquiredimmunodeficiencysyndrome;TB,tuberculosis.
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Antimalarial drugs
The prevalence of malaria in tropical countries results in 
antimalarials being the most widely taken drug and therefore 
often described as “blockbuster” drugs for counterfeiters. 
Two thirds of the available antimalarials are reported to be 
counterfeited, eg, for mefloquine and artesunate found in 
Cambodia in 1998, up to 71% and 60%, respectively, were 
reported to be fake.19 In addition, chloroquine was reported to 
be substituted for artesunate and mefloquine tablets contained 
sulphadoxine-pyrimethamine. Since 1998, between 38% 
and 53% of the artesunate blister packages were reported 
to contain no API, with some counterfeits containing only 
minimal amounts of artesunate. In Cambodia, an effort has 
been made to address the quality of antimalarials in both 
the public and the private health sectors, where 79% of the 
451 drug samples collected in 2006 were not registered 
with the Cambodian Department of Drugs and Food.19 This 
resulted in the National Malaria Control Program taking 
action and attempting to alert both the population and the 
health departments about these counterfeit antimalarials.19 
Although the National Malaria Control Program has pro-
moted the use of good quality antimalarials through both the 
private and public sectors, there was a concern that over 82% 
of the population acquired these products from the private 
rather than public sector. In addition, for those people living 
in remote areas, the problem is exacerbated because they 
are less informed and there is increased tendency for people 
in these locations to buy cheaper drugs from local outlets.19 
Newton et al11 have continued to highlight that counterfeit 
medicines have the most profound effect on disadvantaged 
people in poor countries, usually in the developing world. 
Although they addressed anti-infectives in general, particular 
attention was paid to antimalarials as they are the most widely 
taken drugs in tropical countries.11 These authors recommend 
that to combat the counterfeiters, good quality anti-infectives 
should be available at an affordable price. However, to achieve 
this, there is a need for adequate information on the quality of 
the drug supply in the “real life” situation. Although clinical 
trials to determine the appropriate antimalarials for use in 
particular countries20 have been undertaken, unfortunately 
this is of little use if the supply of quality antimalarial drugs 
is not maintained and monitored.
Newton et al21 reported that the efficacy of artesunate as 
a key treatment for multidrug resistant malaria in mainland 
southeast Asia was being compromised by the widespread 
occurrence of counterfeit artesunate tablets. The inaction of 
international organizations, such as WHO, was reported to be 
due to a lack of resources and regulation, but more  importantly, 
also due to a lack of knowledge of the impact of the fake arte-
sunate.22 This is due to the many deaths of people in rural 
locations not being attributed to fake antimalarials.22
In southeast Asia from 2002 to 2003, up to 53% of 
the artesunate in blister packages was reported to be fake, 
with counterfeit types classified by packaging and fake 
holograms encountered in the People’s Republic of China.23 
This highlighted the increasing level of sophistication of the 
counterfeiters. Because it is one of the most threatened foci 
of malaria, the Greater Mekong subregion has also been the 
subject of an investigation into the emergence of artemisinin 
resistance, with the existence of counterfeit or substandard 
medicines being attributed to worsening the situation.23 It has 
been reported that countries in the Greater Mekong subregion 
face a greater challenge when compared to African countries 
in combating the threat of counterfeit antimalarials.23 Even 
though there are superior legislative procedures in countries 
such as Thailand, a study in 80 outlets revealed that 15.4% 
of the artesunate, 11.1% of the chloroquine, and 29.4% of 
the quinine were substandard.23
In 2012, Nayyar et al24 reviewed the chemical analyses 
and packaging of antimalarial drugs to identify poor qual-
ity antimalarials in southeast Asia and sub-Saharan Africa. 
Although the global burden of malaria has reduced in the past 
decade, there is concern that these poor quality antimalarials 
are likely to put into jeopardy the progress that has been made 
in these regions in eliminating malaria. Results achieved were 
similar for the two regions, especially in relation to failed 
packaging analysis. For southeast Asia (sub-Saharan Africa), 
46% (35%) failed the chemical analyses, 36% (35%) failed 
packaging analysis, and overall, 36% (20%) were classified as 
falsified. Despite a multifaceted approach needed to address 
the issue, empowering of regulatory agencies to protect drug 
supply is seen as key to addressing the problem.24
Counterfeiting of antimalarials poses a significant 
public health problem worldwide. Rapid, reliable, and 
inexpensive methods are needed to screen for the quality 
of these antimalarial drugs. Chemical characterization of 
counterfeit antimalarials involves investigating both their 
drug content and dissolution. It is important, especially in 
developing countries where advanced techniques are not 
available, that simple and affordable field methods be used 
to determine drug content. Raman spectrometry, which does 
not require sample preparation and allows analysis through 
a blister pack, presents a good option for the determination 
of drug  content. Limitations of this method include a lack of 
sensitivity and the requirement that the practical utility of 
the portable Raman unit in the field be further investigated.25 
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Green et al26 put forward the combined use of refractometry 
and colorimetry as an appropriate method for field use to 
assess antimalarial drug quality. Colorimetry makes use of 
color changes from specific chemical reactions, does not 
require toxic organic solvents, and makes use of a portable 
battery powered photometer. A refractometer, which is 
inexpensive and portable, also provides a rugged measure of 
the refractive index of a drug solution, a common physical 
property which can be used to identify counterfeits. Results 
from method bias, sensitivity, specificity, and accuracy 
relative to high performance liquid chromatography indi-
cated that these techniques provide a simple, accurate, and 
affordable means to determine drug quality in resource 
poor settings and are thus appropriate for use in develop-
ing countries. Newton et al11 also highlight the importance 
of dissolution studies to provide information on in vivo 
bioavailability. Poor drug dissolution may not be due to 
the incorrect amount of API, but be due to the incorrect 
excipients and/or poor manufacturing procedures. Disso-
lution, which reflects drug absorption, bioavailability, and 
ultimately efficacy, is thus critical to ensuring the quality 
of antimalarial drugs.11
Antiretroviral and antituberculosis drugs
The impact of counterfeit drugs has the potential to escalate 
toward a macroeconomic pandemic if the emergence of drug 
resistance and mutation of viruses, especially in the treatment 
of HIV/AIDS occurs, resulting in populations which are too 
ill to work in addition to overwhelming the health resources of 
their respective countries.16 Although there are not sufficient 
data to confirm whether resistance to antiretrovirals (ARVs) 
is due to counterfeit drugs or natural resistance, increasing 
resistance has been reported in the United Kingdom, Spain, 
and Brazil. In India, a high prevalence of HIV-1 and HIV-2 
coinfections has resulted in it being necessary for more 
expensive ARV therapies to be used.16 Trade in counterfeit 
drugs is responsible for increasing drug resistance among the 
infectious diseases, including tuberculosis and HIV/AIDS. 
A study in Botswana, reported in 2005, found that 315 of 
the drugs used in tuberculosis treatment were substandard, 
either containing toxic ingredients or no API.16 It is ironic 
that the many  millions of dollars contributed by governments 
of developing countries from their limited resources and that 
are donated from developed countries to treat HIV/AIDS 
and tuberculosis are attracting criminals who are playing 
a role in setting this pandemic in motion. It has also been 
reported by Ahmad27 that antidepressants are being sold as 
ARVs in the Democratic Republic of Congo.  Fluvoxamine, 
an antidepressant and cyclobenzaprine hydrochloride, and a 
muscle relaxant, has been labeled as Triomune®, which is a 
combination of stavudine, lamivudine, and nevirapine, and 
Duovir®, a combination of zidovudine and lamivudine, two 
commonly prescribed ARV brands. The prevalence of HIV/
AIDS in the Democratic Republic of Congo, which has been 
made worse by the long civil war, ranges from 5% to 15%, 
with many people relying on counterfeit medicines, because 
of price and the shortage of good quality ARVs.27 Fears et al28 
have also reported on the re-emergence of tuberculosis in the 
European Union (EU) and its failure to respond to the global 
tuberculosis threat. They also advocated for a humanitarian 
role for the EU to support tuberculosis control in developing 
countries.28
Medical devices
Medical devices (MDs) and in vitro diagnostics (IVDs) are 
a wide range of products and include those simply used as a 
tongue depressor to very complex equipment, with IVDs used 
to examine human specimens in vitro. Although the primary 
action of these devices is not pharmacological, they are how-
ever not exempt from counterfeiting with WHO reporting29 in 
2010 that over 8% of these devices in circulation were coun-
terfeit. The market in these devices is set to increase by 50% 
in 2014, which highlights their increasing role in health care. 
 However despite this, there are significant differences between 
 developed countries such as Australia, Canada, the EU, and 
the United States and resource limited developing countries, 
not only in their quality but in the ability of countries to access 
these products. Again there is a tension between the defini-
tions for counterfeit and substandard devices. Counterfeit 
devices have been defined in line with counterfeit products 
to be those which are deliberately mislabeled, whereas those 
substandard IVDs do not meet specifications and/or contain 
labeling errors. Mori et al30 undertook a detailed review of the 
literature and reported on low quality MDs/IVDs in resource 
limited countries. Table 3 presents a summary of their findings, 
giving examples of MDs/IVDs all performing poorly in rela-
tion to a reference product. It is important to note that climatic 
conditions do have some effect on the performance of these 
products, with poor performance often found during use in 
tropical conditions. A further limitation was the inability to 
distinguish whether performance of the MD/IVD was related 
to quality or poor practices.
These data are however limited by the fact that there are 
very few reports in the scientific literature, with much of the 
information from the gray literature, especially in relation 
to HIV/AIDS and Dengue test kits. In addition, the poor 
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practices in terms of poor laboratory practices and lack of 
training, including the ability to interpret results will also 
play a role in concealing inaccurate diagnoses due to poor 
quality IVDs.38
Addressing the issue of counterfeit 
medicines
Regulation
Adulterated medicines were reported to exist as early as the 
fourth century BC, with warnings to people about the harmful 
nature of these medicines. Changes over the years have seen 
increases in the expertise of the counterfeiters and the extent 
of the problem. Seear39 has highlighted that counterfeiting is 
only one cause of poor drug quality and that reliable research 
into the extent of counterfeiting is lacking with no randomized 
studies of drug quality undertaken in either China or India. 
Despite all the technological advances, this problem still exists 
and has prompted WHO to put out a set of guidelines to inform 
the development of national strategies to combat counterfeit 
medicines, in addition to suggested approaches to detecting 
and monitoring these drugs, including staff training.40 Much of 
these efforts have been limited at the international level by the 
confusion around the definition of counterfeit  medicines. This 
has been attributed to the inability to distinguish between intel-
lectual property rights, trademark protection, and authenticity 
and correct representation of drug content and quality.41 The 
requirement is that this global threat requires solutions which 
are global, regional, and national and there is some frustration 
that despite the establishment of IMPACT in 2006,15 little has 
been achieved.
The Medicrime Convention was drafted by the Council of 
Europe in 2010 to include for the first time an international 
standard criminalizing the manufacture and distribution 
of counterfeit medicines.15 This approach is limited as this 
standard can impede the introduction of new generic drugs 
into these markets, criminalize manufacturers for legitimate 
mistakes, and most importantly, it is distrusted by developing 
countries, especially India and Brazil. These views have been 
summarized by Bate and Attaran42 who indicate that these 
European officials lack the credibility to effect a global drug 
treaty, which should have been the responsibility of WHO, 
through the global initiative, IMPACT.
Frustrations raised by developing countries, especially 
India and Brazil, have included: the lack of accountability 
of IMPACT to WHO, the role of WHO as a public health 
organization and not an enforcement agency for intellectual 
property law, the fact that member states did not endorse 
WHO to be a secretariat of IMPACT, and the need for 
WHO support of developing countries.43 There was also 
concern about the lack of transparency in terms of the 
involvement of IMPACT with big pharma and its role in 
enforcing intellectual property rights rather than serving 
the purpose of public health. This inability to maintain 
balance between intellectual property and drug quality has 
resulted in IMPACT moving its secretariat from Geneva 
to Italy,43 and thus in 2012, members welcomed the estab-
lishment of the new member state mechanism (MSM),44 a 
governance structure to address the issue of poor quality 
medicines.
The 65th World Health Assembly in 2012 put forward new 
tools to combat what they defined as substandard/spurious/
falsified/counterfeit medicines.45 Recommendations were to 
focus on the public health implications of these medicines 
whilst providing support for the establishment of the New 
Member States Mechanism 45 within the framework of WHO 
to facilitate information exchange and foster international 
collaboration to combat these medicines. In addition, member 
states undertook to develop direction tools, build capacity, 
establish global monitoring systems, and more importantly, to 
assess risk in the allocation of resources taking into account 
their national context. Interestingly, a workshop was also held 
on the regulation of medical devices for the first time, with 
the outcome of suggested collaborations between regulatory 
authorities in developed countries with those countries with 
less developed systems.45
At a regional level, harmonization of medicine registra-
tion and regulatory activities are being addressed, eg, by the 
African Medicines Regulatory Harmonization Initiative. This 
Table 3 examples of quality issues related to medical devices and 
in vitro diagnostics
Test type Area Quality Date/reference
Microkeratomes Asia Manufacturer  
specifications
200131
Blood glucose  
meter
Africa Sensitivity –  
tropics
200332
Boehringer 
Mannheim­lactate 
test strips
Asia Tampered  
expiry date
200433
Antibiotic discs Asia inconsistent  
results
200634
Antiseptic South America Substandard  
efficacy
200635
Antibiotic discs South America inconsistent  
results
200736
Fuchsin dye Africa/Asia impurity in  
powders
200937
Note: Data from Mori et al.30
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initiative aims to use scarce resources to improve standards, 
including addressing the issue of poor quality and counterfeit 
drugs.46
The United States Pharmacopeial Convention has also 
undertaken to train medicine regulatory officers at a train-
ing center established in Ghana, so that African nations 
can address the issue of regulation of drugs in the region.47 
Although the United States Pharmacopeial has contributed 
funding for this initiative, it is expected that the member 
countries, currently including Ghana, Ethiopia, Kenya, 
Senegal, Sierra Leone, and Nigeria will begin to contribute 
financially. These programs will include training in dossier 
evaluation, good manufacturing practice, and laboratory 
techniques. The plan to build a quality control laboratory, 
which will charge for services, has attracted the interest of 
local pharmaceutical industries, who due to their own lack 
of infrastructure see this as an opportunity to undertake 
the testing of their products. This training center is seen as 
providing an important opportunity for countries to share 
information on counterfeit medicines.47
At a national level, despite the growth in technology 
including screening devices in the field and the use of text 
messages by consumers, regulation continues to present a 
challenge in developing countries. A study was undertaken 
in Tanzania to identify whether reforms of pharmaceutical 
policy were undertaken to in fact improve efficiency or 
whether they just presented an opportunity for vested inter-
ests.48 Findings from the study highlighted the influence of 
politics on decision making at many levels of the reform 
process, with regulation remaining a challenge. There is a 
call on governments to limit the political influence on policy, 
in the interests of appropriate public health outcomes for the 
populations of developing countries.48
Despite all these efforts, ineffectual governance and diver-
gent interests are reported by Mackey and Liang49 to be the 
reason for the limited surveillance of counterfeit medicines 
and the continuing global public health threat. Despite the 
fact that as early as 1988, the World Health Assembly of 
WHO called for global action on counterfeit medicines in 
the interest of medicine safety, arguments over terminology 
have detracted attention from the crisis and the threat to public 
health. These authors therefore have suggested the formation 
of an enhanced global health governance trilateral mechanism 
between the WHO, the United Nations Office of Drugs and 
Crime (UNODC), and Interpol to optimize both the strengths 
and resources of these organizations. This proposal has been 
made because of the lack of enforcement capabilities of the 
WHO, and their conflict between representing public health 
needs and that of intellectual property. UNODC and Interpol 
have been suggested as partners in the trilateral mechanism 
due to the need for effective engagement against the criminal 
networks involved in counterfeiting. Since UNODC50 previ-
ously engaged in global health by participating in HIV/AIDS 
prevention and specializes in establishing policy to combat 
transnational crime, this should provide WHO with the free-
dom to redirect its efforts toward the protection of patient 
safety to achieve an improved public health outcome.
Quality
Controlling the quality and limiting drug counterfeiting 
requires different strategies in developing countries as 
compared to the developed world.51 Anticounterfeit mea-
sures using the short messaging service verification system 
was effective in developing countries including Ghana, 
Nigeria, and Kenya, with an announcement in early 2012 
that more than one million people had used this system to 
verify the authenticity of their medicines.51 Since labeling 
allows manufacturers to monitor different batches of prod-
uct, radiofrequency identification (RFID) using electronic 
devices to track and identify items ensures that the supply 
chain not only becomes more secure, but also efficient. 
The limitation of the short messaging service technology 
is that unlike the RFID, it cannot be traced and therefore 
is exposed to the potential of cloning by the counterfeiters. 
Serialization presents the advantage of uniquely identifying 
every item with a serial number stored in the RFID tag or in 
a bar code, with verification of these codes to be undertaken 
at the point of purchase. This system has been successfully 
implemented in North America and the recommendation is 
for use in developing countries.51 It has been concluded that 
ensuring maximum traceability and authenticity through the 
use of this technology has contributed to the low level of drug 
counterfeiting in developed countries.
The expansion in the number of pharmaceutical manu-
facturers in China and India and in the developed world 
has increased. This expansion includes in Kenya, Uganda, 
and Nigeria to accommodate the growing demand for 
 pharmaceuticals and is good in that it has driven down the 
price of these products. However, this benefit is only of 
value if these products are in fact therapeutically equivalent 
to the original products and their quality is comparable. Bate 
et al52 have determined the quality of 1,912 drug samples 
from countries with emerging economies using basic thin 
layer chromatography and disintegration tests (failure rate of 
3.8%). They then compared the results with those achieved 
using Raman spectroscopy (failure rate of 5.2%). Their 
Research and Reports in Tropical Medicine 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
19
Counterfeit drugs and medical devices
Table 4 Analytical techniques used to detect counterfeit medicines
Technique Description Drugs Limitations cost Technology
Near­infrared  
spectroscopy54
NiR is rapid and simple 
Physical and chemical  
testing
Trimethoprim/ 
sulfmethoxazole 
Drotaverine 
Metronidazole
NiR systems routine in  
laboratories but portable 
NiR for onsite 
**
inclusion of 
chemometric analysis 
*
Near­infrared  
spectroscopy55 
chemometric analysis
NiR spectra acquired  
and compared to  
reference spectra
Spectra of drug  
in packaging 
Paracetamol tablets
NiR systems spectrometer 
*
Reference spectra 
inclusion of 
chemometric analysis 
*
Near­infrared  
spectroscopy56 
Multivariate  
classificationmodels
NiR spectra acquired  
and compared to  
reference spectra
Artesunate tablets NiR system US$45,000 – a  
lower cost silicon­based  
instrument US$5,000 
**
Portable NiR battery 
powered 
Training minimal after 
calibrations – basic 
computer skills 
**
Capillary  
electrophoresis57
Analyze compounds with 
good selectivity; simple, 
rapid, and reliable
Quinine 
Furosemide 
Trimethoprim/ 
sulfmethoxazole
Cost of reagents and thus 
analysis low and low cost 
maintenance 
**
Compared low cost 
Ce equipment to 
conventional setup 
**
Liquid 
chromatography58,59
Analyze with good  
specificity,accuracy, 
precision
Antibiotics 
 Ampicillin 
 Amoxicillin 
 Doxycycline 
Antimalarials 
 Quinine 
 Chloroquine 
 Mefloquine
Reagents costly and high  
cost equipment 
Advantage: 
One method for a number 
of drugs 
*
Highly trained 
personnel, specialized 
equipment/maintenance 
*
Fast chemical  
identificationsystem60
Color reactions based  
on functional groups/thin 
layer chromatography
Macrolide antibiotics Simple, rapid, cost  
effective for use onsite 
*** 
Lacks sensitivity of LC to 
identify the drug
equipment simple, 
limited expertise 
required 
***
Gas chromatography/ 
mass spectrometry61
Residual solvents higher 
than genuine products – 
also often toxic
Sildenafiland 
Tadalafiltablets
High cost equipment but 
rapid, simple to undertake 
*
Specialized equipment, 
limited training 
required/maintenance 
**
Raman microscopy  
and 2D correlation  
spectroscopy62
Chemically analyze the 
box colorants and visual 
inspection
Packaging 
Tadalafiltablets
Raman microscope, high 
cost equipment 
*
Specialized equipment, 
trained personnel 
required/maintenance 
*
Calorimetry63 Reflectancevisible 
spectrum of solid material
PackagingSildenafil 
tablets
Colorimeter 
Low cost 
Limitations: 
Reference library 
Low precision for convex 
tablets 
***
Simple equipment, easy 
to operate, limited 
maintenance 
***
Notes: Cost is designated as: ***affordable; **medium affordability; and *not affordable. equipment and expertise (technology) is designated by the level of applicability to 
developing countries as: ***applicable; **medium applicability; and *not applicable.
Abbreviations: Ce, capillary electrophoresis; LC, liquid chromatography; NiR, near­infrared spectroscopy.
findings indicated that the failure rate of drugs produced by 
African companies was 8.3% and that these failures were 
relatively higher amongst antimalarials than antibiotics. 
This study highlights the problem in Africa, and is attributed 
to poor manufacturing locally and the fact that low quality 
drugs are able to infiltrate into the supply chain. In addition, 
this research has drawn attention to the issue of substandard 
drug products, especially because of the potentially lethal 
nature of the infections that these products are being used to 
treat. The relevance of this work in relation to substandard 
medicines is confirmed by Kaltenboeck et al53 who have 
reviewed the literature on the use of imatinib in the treatment 
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of chronic myeloid leukemia. In assessing whether the litera-
ture provides evidence of the safety and efficacy of generic 
imatinib, their findings indicate that there are significant 
gaps in interpretability and quality. This highlights a need 
for information, where the bioequivalence of the generic 
products is compared to that of the original medicines, and 
the greater need for pharmacovigilance to assess both the 
impact of these medicines and their effect on patient safety. 
Table 4 presents a summary of various analytical techniques 
that have been developed to discriminate between counter-
feit and genuine products. Although these techniques have 
evolved over the past 10 years and are being applied very 
successfully in the developed countries, there are limitations 
in terms of cost and the sophistication of the technology in 
relation to both instrumentation and lack of an appropriately 
trained workforce in developing countries.
Supply chain
The complexity of the supply chain for pharmaceuticals has 
been identified as contributing to the market for counterfeit 
medicines.65 There is a requirement that the supply chain be 
fit for purpose to ensure the safe supply of medicines. This 
supply chain begins with the raw materials and ends with the 
finished product, delivered to the patients, ensuring that there 
has been no tampering, diversion, falsification, substitution, 
or adulteration.64 Pharmacists, because of the various posi-
tions that they hold in the supply chain and their expertise 
in drugs and drug products, are said to have a role to play in 
securing the supply chain. This has been highlighted by the 
call for updating training programs for pharmacists in India, 
with extension of their role to creating awareness among all 
health professionals.65 An innovative solution to decrease 
the complexity of the supply chain has been put forward by 
Cozella et al66 who proposed that drug packaging security be 
achieved by the application of white light speckle theory to an 
ultraviolet (UV) source linking packaging to a barcode. Both 
direct and indirect technology may be used to optimize the 
security of packaging. Direct technology offers the consumer 
the opportunity to visually inspect the packaging and includes 
such techniques as holograms and color shift inks. Barcodes 
and RFID allow electronic control of the products within the 
sale system. RFID could be used in developing countries, 
even accounting for poor electricity supply by integration 
with cell phones. Indirect technology however is reliant on 
expertise, dedicated instrumentation, and is characterized by 
its invisibility and includes the use of UV inks, color, and 
UV microtext print taggant and laser surface authentication. 
Physical unclonable function (PUF) involves the inclusion of 
chemical particles randomly into packaging, with white light 
speckle as a PUF being put forward as an alternative to a laser 
speckle method. This is advantageous as PUF only requires 
incoherent light  illumination, with a surface with speckle-like 
reflectivity applied by spraying with retroreflective paint.66
Conclusion
Drugs make an essential contribution to the quality of life, 
human dignity, and self-esteem of populations worldwide and 
are significant to people being employed and the subsequent 
economic and social upliftment of entire populations, espe-
cially in the developing world. Although counterfeit drugs 
present a global problem, there is however a vast difference 
between the nature of the drugs counterfeited in develop-
ing countries and those in developed countries. Primarily 
expensive lifestyle drugs such as sildenafil and tadalafil 
are counterfeited in the developed world, while those drugs 
frequently counterfeited in developing countries are to treat 
life threatening diseases such as malaria, tuberculosis, HIV/
AIDS, and other serious infectious conditions. Kelesidis 
et al67 in their review of the scientific evidence on counter-
feit or substandard antimicrobial drugs have highlighted the 
consequences for patients and society of these low quality 
antimicrobials. Although challenges worldwide include the 
increasing sophistication of the counterfeiters, the lack of an 
international “fake” drug treaty, the lack of laws to pursue 
the counterfeiters of drugs (with these laws in place for other 
intellectual property infringements), and the expansion of 
counterfeiting to all therapeutic fields including expensive 
cancer medicines, there is an increased level of complexity 
to resolving this issue in the developing world. Essential 
drugs are important to public health programs, aimed at 
reducing mortality and morbidity in the developing world, 
where poor quality and counterfeit drugs represent only one 
of the issues associated with the lack of accessibility to drugs 
for these populations. A lack of access, which is attributed 
to economic reasons, is yet another factor which divides 
the developed and developing world and has resulted in an 
increase in counterfeit products in developing countries over 
the past 10 years, providing a very fertile market of desperate, 
uninformed, and unsophisticated people.
As early as 1997, Shakoor et al68 reported on the need 
to assess the incidence of substandard drugs in develop-
ing countries, which is prevalent due to poor regulation 
and control in these drugs, unlike in the developed 
world. As a result it might be difficult to distinguish 
whether increasing drug resistance is due to counterfeit 
or substandard medicines, or both. In these developing 
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countries, if a product fails a pharmacopoeial test, it can-
not be assumed that it is  counterfeit, with a lack of good 
manufacturing practice, adequate quality assurance and 
drug degradation, or decomposition due to inappropriate 
packaging and storage all potential contributors to the 
substandard quality of these products. This was again 
addressed by Ravinetto et al69 after almost 15 years, 
who reported that although there have been a number 
of initiatives globally attempting to address counterfeit 
medicines, the issue of substandard medicines has been 
neglected and in the developing world these medicines 
are not only widespread, but are as dangerous as counter-
feits. Tremblay64 concurs with these findings identifying 
that the complexity related to counterfeiting is due to the 
consumer not being informed, the Internet exacerbating 
the problem, the criminal element associated with coun-
terfeiting, and the fact that substandard medicines may 
be a bigger problem. While much effort has been focused 
on the development of sophisticated analytical methods 
to detect counterfeit drugs, these methods are only really 
applicable in the developed world. It is hoped that mea-
sures will also be put in place to address this real public 
health problem and to prevent the appearance of poor 
quality products, whether medicines or devices, to protect 
the interests of patients worldwide, especially those most 
vulnerable in the developing countries.
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